Celgene’s Phase 3 Study of Arthritis Drug Misses Target

July 9, 2014 11:51 AM

14 0

Celgene Corp. said Wednesday that its Phase 3 trial of a drug intended to treat a form of long-term arthritis didn’t meet its primary endpoint after a certain period, although results showed improvement beyond that.

The company said an independent data monitoring committee recommended that the study of Otezla for treating patients with ankylosing spondylitis continue without any changes.

Also read: CES 2018: Cool gadgets from the show

Read more

To category page